A small number of GHR antagonists have been used in an oncology settings in preclinical studies and the growth-inhibiting effects have been reported in colon, breast, and meningioma tumor xenografts, which suggested that GHR antagonism as a monotherapy is efficient in some tumor types (Friend, 2001; McCutcheon et al., 2001; Dagnaes-Hansen et al., 2004; Divisova et al., 2006). This evidence concerns the gene GHR and meningioma.